Globally, 50-70% of term and 80% of preterm babies develop neonatal jaundice, a pathological condition involving raised levels of bilirubin. Babies usually recover within the first week without requiring treatment.

However, for cases where bilirubin levels are dangerously high, phototherapy is administered to trigger the breakdown of bilirubin into easily-excretable molecules, preventing bilirubin neurotoxicity in infants.

Our product, BiliMonitor++, is a home phototherapy device primarily utilizing sunlight to treat neonatal jaundice. By avoiding expensive equipment and instead using naturally-occurring resources, it strives to increase accessibility and affordability of neonatal jaundice treatment, delivering high-quality and effective care to infants in rural regions.